Last edition
News about "Taiho Pharmaceutical"
US FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC
Calderasib has received US FDA Breakthrough Therapy Designation for certain patients with newly diagnosed metastatic KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC), supported by promising phase 1 KANDLELIT-001 trial data highlighting its potential as a next-generation, highly potent and selective KRAS G12C inhibitor.
Taiho Pharmaceutical | 30/05/2026 | By News Bureau | 108
US FDA Approves INQOVI Plus Venetoclax for AML
The US Food and Drug Administration (FDA) approves INQOVI with venetoclax as the first all-oral combination treatment for acute myeloid leukemia patients ineligible for intensive chemotherapy, supported by positive ASCERTAIN-V trial data.
Taiho Pharmaceutical | 14/05/2026 | By News Bureau | 121
JFCR, NEC and Taiho Partner on Whole-Genome Driven Cancer Vaccine Research
JFCR, NEC, and Taiho have launched a joint research initiative to develop novel cancer vaccines using whole-genome data. The project is part of AMED’s national programme on whole-genome analysis, supporting efforts to demonstrate its clinical utility and build systems that translate genomic insights into patient benefits.
Taiho Pharmaceutical | 01/12/2025 | By Dineshwori | 165
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy